SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006263
Filing Date
2021-05-06
Accepted
2021-05-06 16:34:45
Documents
43
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20210331x10q.htm 10-Q 579946
2 EX-31.1 apre-20210331ex31119fc27.htm EX-31.1 9743
3 EX-31.2 apre-20210331ex312c18759.htm EX-31.2 9734
4 EX-32.1 apre-20210331ex3217bd7ca.htm EX-32.1 6726
5 EX-32.2 apre-20210331ex322df35c4.htm EX-32.2 6719
  Complete submission text file 0001558370-21-006263.txt   2095362

Data Files

Seq Description Document Type Size
6 EX-101.INS apre-20210331.xml EX-101.INS 290466
7 EX-101.SCH apre-20210331.xsd EX-101.SCH 21197
8 EX-101.CAL apre-20210331_cal.xml EX-101.CAL 29384
9 EX-101.DEF apre-20210331_def.xml EX-101.DEF 33639
10 EX-101.LAB apre-20210331_lab.xml EX-101.LAB 191777
11 EX-101.PRE apre-20210331_pre.xml EX-101.PRE 125371
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 21898432
SIC: 2834 Pharmaceutical Preparations